Trial · NCT00895830

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

NCT00895830, Phase 2, Completed, Acacia Pharma Ltd; results first posted 2011-03-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV). Trials, record NCT00895830. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00895830

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
NCT number: NCT00895830
Status: Completed
Phases: Phase 2
Enrollment: 257 participants, actual
Lead sponsor: Acacia Pharma Ltd
Conditions: Postoperative Nausea and Vomiting
Interventions: APD405, Placebo
First posted: 2009-05-08
Last updated: 2011-03-29
Results first posted: 2011-03-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Experienced Post-operative Nausea or Vomiting	24 hours

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Experienced Post-operative Nausea or Vomiting	24 hours	ITT	participants	NUMBER

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Experienced Post-operative Nausea or Vomiting	Placebo	25	participants
Experienced Post-operative Nausea or Vomiting	APD405 0.3mg Dose	29	participants
Experienced Post-operative Nausea or Vomiting	APD405 1mg Dose	20	participants
Experienced Post-operative Nausea or Vomiting	APD405 2mg Dose	30	participants
Experienced Post-operative Nausea or Vomiting	APD405 3mg Dose	28	participants

Source ClinicalTrials.gov

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	51
Overall Study	STARTED	APD405 0.3mg Dose	50
Overall Study	STARTED	APD405 1mg Dose	49
Overall Study	STARTED	APD405 2mg Dose	52
Overall Study	STARTED	APD405 3mg Dose	55
Overall Study	COMPLETED	Placebo	51
Overall Study	COMPLETED	APD405 0.3mg Dose	50
Overall Study	COMPLETED	APD405 1mg Dose	49
Overall Study	COMPLETED	APD405 2mg Dose	52
Overall Study	COMPLETED	APD405 3mg Dose	55

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events90

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Procedural pain	Injury, poisoning and procedural complications	Placebo	24	51
other	Procedural pain	Injury, poisoning and procedural complications	APD405 0.3mg Dose	25	50
other	Procedural pain	Injury, poisoning and procedural complications	APD405 1mg Dose	32	49
other	Procedural pain	Injury, poisoning and procedural complications	APD405 2mg Dose	25	52
other	Procedural pain	Injury, poisoning and procedural complications	APD405 3mg Dose	24	55
other	Nausea	Gastrointestinal disorders	Placebo	26	51
other	Nausea	Gastrointestinal disorders	APD405 0.3mg Dose	28	50
other	Nausea	Gastrointestinal disorders	APD405 1mg Dose	20	49
other	Nausea	Gastrointestinal disorders	APD405 2mg Dose	30	52
other	Nausea	Gastrointestinal disorders	APD405 3mg Dose	25	55

1 to 10 of 90Source ClinicalTrials.gov

See all 90 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	APD405 0.3mg Dose
Total, all-cause mortality	APD405 1mg Dose
Total, all-cause mortality	APD405 2mg Dose
Total, all-cause mortality	APD405 3mg Dose
Total, other adverse events	Placebo	46	51
Total, other adverse events	APD405 0.3mg Dose	46	50
Total, other adverse events	APD405 1mg Dose	45	49
Total, other adverse events	APD405 2mg Dose	45	52
Total, other adverse events	APD405 3mg Dose	51	55

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22546895	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00895830

GET https://conductscience.org/api/trials/v1/NCT00895830/events?page=2

API reference For AI assistants